Risk Factors for Invasive Infection in Febrile Oncology Patients Related to Cancer Type

View at publisher
Authors: Borja Gómez, Oriol Quintana, Mirian Soriano Moreno, Ricardo López Almaraz, Fernando Almarza, Santiago Mintegi
Cited by: 0

Abstract

OBJECTIVE: To identify clinical and laboratory risk factors for invasive infection in febrile oncology patients seen in the Pediatric Emergency Department, depending on the type of cancer. METHODS: We conducted a prospective observational study of febrile oncology patients seen between 2016 and 2023 at the Pediatric Emergency Department of a tertiary teaching hospital. Invasive infection was defined microbiologically (isolation of a bacterial pathogen in sterile fluid or a commensal bacterial species in 2 different blood cultures) or clinically (death, meeting Phoenix criteria for sepsis, receiving inotropic support, or developing acute complications or sequelae). We performed separate multivariate analyses for hematologic cancers and solid tumors. Hematologic cancers were further classified considering the myelotoxicity of the chemotherapy received. We classified the following as high-risk hematologic cancers: acute lymphoblastic leukemia and non-Hodgkin lymphoma in the induction, reinduction, or consolidation phase or relapse, and acute myeloid leukemia in any phase. RESULTS: We included 471 episodes: 306 hematologic cancers and 165 solid tumors. The median age was 4 years (interquartile range: 2 to 10) and the median duration of fever was 2 hours (interquartile range: 1 to 3). Invasive infections were diagnosed in 69 cases (14.6%). The rate was higher among patients with high-risk hematologic cancers (n=45, 23.2%), than among those with solid tumors (n=18, 10.9%; P =0.002) or with low-risk hematologic cancers (n=6, 5.4%; P

Fields of Study & Subjects

Neutropenia and Cancer Infections Sepsis Diagnosis and Treatment Antifungal resistance and susceptibility

Publication details

Journal / source
Pediatric Emergency Care
Volume
42
Issue
6
Pages
440–445
Publication date
9 February 2026
Language
EN